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Pathophysiology, Clinical Importance, and Management of
Neurogenic Lower Urinary Tract Dysfunction Caused by Suprasacral
Spinal Cord Injury
H.Z. Hu, N. Granger, and N.D. Jeﬀery
Management of persistent lower urinary tract dysfunction resulting from severe thoracolumbar spinal cord injury can be
challenging. Severe suprasacral spinal cord injury releases the spinal cord segmental micturition reﬂex from supraspinal mod-
ulation and increases nerve growth factor concentration in the bladder wall, lumbosacral spinal cord, and dorsal root gan-
glion, which subsequently activates hypermechanosensitive C-ﬁber bladder wall aﬀerents. Hyperexcitability of bladder
aﬀerents and detrusor overactivity can cause urine leaking during the storage phase. During urine voiding, the loss of
supraspinal control that normally coordinates detrusor contraction with sphincter relaxation can lead to spinal cord segmen-
tal reﬂex-mediated simultaneous detrusor and sphincter contractions or detrusor-sphincter dyssynergia, resulting in ineﬃcient
urine voiding and high residual volume. These disease-associated changes can impact on the quality of life and life expectancy
of spinal-injured animals. Here, we discuss the pathophysiology and management considerations of lower urinary tract dys-
function as the result of severe, acute, suprasacral spinal cord injury. In addition, drawing from experimental, preclinical,
and clinical medicine, we introduce some treatment options for neurogenic lower urinary tract dysfunction that are designed
to: (1) prevent urine leakage arising because of detrusor overactivity during bladder ﬁlling, (2) preserve upper urinary tract
integrity and function by reducing intravesical pressure and subsequent vesicoureteral reﬂux, and (3) prevent urinary tract
and systemic complications by treating and preventing urinary tract infections.
Key words: Cystometry; Dog; Spinal; Urinary; Urodynamics.
Management of lower urinary tract dysfunction isfrequently a long-term problem in pet dogs that
incur severe spinal cord injury. Currently, management
consists primarily of regular manual bladder expression,
periodic urinalysis, and bacteriological culture, plus
symptomatic antibiotic treatment and, less commonly,
prophylactic antiseptic treatment, dietary supplements,
or both.1–4 These standard management strategies aim
to address inappropriate reﬂex urine voiding and the
inability to initiate voluntary bladder emptying that can
result in recurrent urinary tract infections, which have
the potential to cause life-threatening ascending
pyelonephritis. In this review, we discuss the neurologic
pathways involved in normal lower urinary tract func-
tion and how these pathways can be altered by spinal
cord injury and result in lower urinary tract dysfunc-
tion. In addition, we outline how these disease-asso-
ciated changes can be diagnosed and monitored using
cystometry. Lastly, drawing from experimental, preclini-
cal, and clinical medicine, we introduce some additional
management considerations and treatment options for
neurogenic lower urinary tract dysfunction.
Functional Anatomy and Neurologic Pathways of
the Lower Urinary Tract
The lower urinary tract consists of an expandable
reservoir, the urinary bladder, that stores urine until
periodic voiding and an outlet consisting of the bladder
neck, urethra, and internal and external urethral sphinc-
ters that permits bladder emptying when intravesical
pressure or volume reach speciﬁc sensory thresholds. In
dogs and cats, the reciprocal mechanisms involved in
urine storage and voiding are mediated by aﬀerent and
eﬀerent impulses that travel in three paired peripheral
nerves, namely the pelvic, hypogastric, and pudendal
nerves, and are coordinated by segmental spinal cord
reﬂexes and supraspinal pathways involving the brain-
stem and cerebral cortex (Fig 1).5,6
The sensory ﬁbers that innervate the lower urinary
tract extend from the bladder wall, bladder neck, and
urethra to the spinal cord via lumbosacral dorsal root
ganglia of the pelvic, hypogastric, and pudendal nerves
and convey sensory information regarding the degree of
bladder distension.6 The relative proportions of sensory
information from the lower urinary tract carried in each
of these three paired nerves vary between species.5–8
For instance, in cats, sensory ﬁbers arising from the
bladder wall stretch receptors and the urethra mainly
travel within the pelvic and hypogastric nerves;7
whereas in dogs, sensory input from the bladder wall
stretch receptors is carried primarily by the pelvic
nerves to the spinal cord.8 In both species the
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hypogastric nerves relay information regarding bladder
overdistension.9 Further distinctions also exist regarding
the speciﬁc spinal cord segments that receive the sensory
input from the lower urinary tract delivered by the
three paired peripheral nerves; for instance, the
hypogastric nerves reach the spinal cord at L2–L5 in
cats10 and L1–L4 in dogs.9
In species including cats, dogs, rats, and humans,
under normal circumstances, myelinated A-delta ﬁber
mechanoreceptors in the bladder wall produce graded
trains of activity in response to bladder distension dur-
ing the storage or ﬁlling phase.6,11–13 The A-delta ﬁber
receptors can change activity in response to noxious
stimuli or when spikes of intravesical pressure ~6.8–
20.4 cmH2O or 5–15 mmHg above resting level
occur.11,12 These normal mechanisms, when disrupted,
can lead to a series of clinical and functional anoma-
lies.11,13–15 In certain species such as the rats, a diﬀerent
class of bladder wall receptors, impulses from which are
carried by unmyelinated C-ﬁbers, also detect gradual
bladder distention during the storage phase, as well as
noxious stimuli.14,15 In contrast, in humans and cats,
C-ﬁber aﬀerent input is normally functionally masked
by A-delta aﬀerent input, which renders the C-ﬁber
aﬀerents functionally silent and unresponsive to gradual
physiologic bladder distension during ﬁlling.11,12,14,15
Axons that normally respond to bladder distension, pri-
marily those that carry sensory information from the
A-delta ﬁber mechanoreceptors, project to various spinal
cord regions including the dorsal commissure, the superﬁ-
cial dorsal horn of the lumbosacral spinal cord, and the
sacral parasympathetic nucleus.15 A-delta ﬁber input
ascends in the spinal cord via the spinothalamic and
spinobulbar tracts; the former reaches the thalamus and
subsequently the suprathalamic centers such as the cere-
bral cortex, thereby conveying conscious sensory informa-
tion, whereas the latter reaches the pontine micturition
center in the brainstem.6 Unmyelinated C-ﬁbers typically
convey sensory information such as autonomic regulation
of micturition that does not undergo conscious processing
and this information ascends in the spinomesencephalic,
spinoreticular, and spinohypothalamic tracts to reach
subthalamic structures in the brain.6,14,15
Two brainstem nuclei, the pontine micturition center
and the periaqueductal gray, receive aﬀerent input pri-
marily from the bladder wall A-delta ﬁbers and can ini-
tiate voiding after communicating with the cerebral
cortex.6 A third brainstem nucleus, the pontine storage
center, is believed to play a role in promoting conti-
nence during bladder ﬁlling by facilitating closure of the
urethral sphincter.14,15 A number of additional brain
areas, including the paraventricular nucleus, periventric-
ular nucleus of the hypothalamus, red nucleus, and
raphe nucleus, also have anatomic connections with the
micturition pathway but their functional connections
are poorly deﬁned.14,16
The pontine micturition center controls autonomic
micturition function via the pontine reticulospinal tract
that regulates the intermediolateral nucleus and sacral
parasympathetic nucleus. The former is distributed
along the intermediate gray matter of the thoracolum-
bar segments, which contains the sympathetic pregan-
glionic neurons; the latter is located in the sacral
intermediate gray matter, which contains parasympa-
thetic preganglionic neurons.14–16 In dogs, the pregan-
glionic nuclei of the sympathetic hypogastic nerves and
parasympathetic pelvic nerves are located in the inter-
mediate gray matter of L1–L3 and S2–S3, respectively.6
When activated, the hypogastric nerves relax the detru-
sor and constrict the urethra and bladder neck to facili-
tate bladder ﬁlling at low intravesical pressures; whereas
the pelvic nerves excite the detrusor and facilitate urine
voiding upon activation.6
Parasympathetic function relies mainly on cholinergic
transmission, whereby postganglionic axonal acetyl-
choline release and binding with muscarinic receptors in
the bladder wall result in detrusor contraction (Fig 1).6
In contrast, sympathetic function is mediated by adren-
ergic transmission through the release of noradrenaline
from postganglionic neuron axon terminals; nora-
drenaline binding with bladder wall smooth muscle
b-adrenergic receptors mediates detrusor relaxation, and
binding with urethral smooth muscle a1-adrenergic
receptors triggers urethral contraction.6,16
Additionally, the cerebral cortex exerts conscious
control of micturition via descending tracts that synapse
with somatic motor neurons of the pudendal nerves in
the sacral ventral horns, speciﬁcally S1–S3 in dogs,
which innervate the external urethral sphincter.6,16 Vol-
untary control of the external urethral sphincter is
mediated by somatic cholinergic transmission; binding
of acetylcholine released from pudendal nerve axon ter-
minals with its nicotinic cholinergic receptors in the
external urethral sphincter muscle produces voluntary
sphincter contraction to maintain continence during
bladder ﬁlling.6,16
Urine Storage and Voiding Mechanisms
Urine storage and periodic voiding depend upon the
reciprocal relationship between reservoir and outlet,
Fig 1. Lower urinary tract innervation and neurotransmitters.
Aﬀerents and eﬀerents travel in paired pelvic, hypogastric, and
pudendal nerves. Parasympathetic and somatic neurotransmission
are mediated by cholinergic ﬁbers; sympathetic function is medi-
ated by adrenergic ﬁbers.
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which is mediated and coordinated by segmental spinal
cord reﬂexes, spinal pathways and supraspinal centers.
During bladder ﬁlling, the detrusor remains in a vari-
able state of relaxation termed “compliance,” allowing
accommodation of increasing volumes of urine without
signiﬁcant increase in intravesical pressure. Gradual
bladder distention stimulates the bladder wall
mechanosensitive A-delta and C-ﬁbers to produce
graded potentials that: (1) stimulate the sympathetic
innervation via hypogastric nerves to simultaneously
contract the bladder outlet and inhibit the detrusor; and
(2) stimulate somatic innervation of the external ure-
thral sphincter via pudendal nerves to prevent leakage
during bladder ﬁlling. Although areas in the lateral
pons, also known as the pontine storage center or
“L-region,” may facilitate involuntary sphincter control,
bladder ﬁlling is largely an involuntary process regu-
lated by sympathetic thoracolumbar and somatic sacral
segmental spinal cord reﬂexes in normal individuals
(Fig 2A).6,11,12,14,16
In contrast, micturition is an active, voluntary pro-
cess coordinated by supraspinal centers, which ensure
that reciprocal detrusor contraction and outlet relax-
ation occur simultaneously when socially appropriate.
Once a certain intravesical volume or pressure per unit
volume threshold—12–32 cmH2O in conscious
humans17–19 and 18 mL/kg or 50 cmH2O in anes-
thetized dogs,13—is reached, the baseline aﬀerent-graded
potentials are overcome by depolarizing action poten-
tials that convey this speciﬁc information to the pontine
micturition center and the cerebral cortex.11,12,14,15 Acti-
vation of the pontine micturition center simultaneously
inhibits the sympathetic and somatic innervation to trig-
ger bladder outlet relaxation and stimulates parasympa-
thetic innervation to initiate and sustain detrusor
contraction until urine voiding is complete (Fig 2B).
Changes in the Lower Urinary Tract after
Suprasacral Spinal Cord Injury
Lower urinary tract dysfunction secondary to supra-
sacral spinal cord injury can result from damage at any
site within the micturition pathway between the sacral
segments and cerebral cortex. Experimental studies in
rats and cats suggest that bladder wall C-ﬁber aﬀerents,
which are usually functionally silent in spinal-intact ani-
mals, can become activated after suprasacral spinal cord
injury.14,15,18,19 The ionic mechanisms underlying
C-ﬁber neuron hyperexcitability were determined by
means of patch clamp, which allows the movement of
ions across transmembrane ion channels to be quanti-
ﬁed.20,21 Whole-cell patch clamp recordings revealed
that the Na+ channels in L6–S1 dorsal root ganglion
neurons from chronic T8–T9 spinal-transected rats have
lower depolarization threshold and shorter action
potential duration.20
Changes in dorsal root ganglion Na+ channel prop-
erties are attributed to a speciﬁc injury-induced switch
in the expression of Na+ channels in favor of those that
have lower thresholds.20 In contrast, the number of neu-
rons innervating the bladder and the electrophysiologic
properties of neurons innervating other pelvic organs
such as the colon, both remain unchanged after spinal
transection.20 Simultaneously, at least the KA, and pos-
sibly other subtypes of K+ channels, are functionally
incapacitated, such that application of a K+ channel
blocker 4-aminopyridine makes no diﬀerence to the
movement of K+ across the L6–S1 dorsal root ganglion
neuron cell membrane.20,21 The net eﬀect of concurrent
Fig 2. Reciprocal actions during urine storage and voiding:
(A) During storage, sympathetic and somatic eﬀerents are activated
to maintain urinary continence; (B) During voiding, parasympa-
thetic eﬀerents are activated to trigger detrusor contractions.
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Na+ channel activation and K+ channel deactivation is
hyperexcitability of the dorsal root ganglion neurons
innervating the urinary bladder.
This change in ion channel expression in dorsal root
ganglion neurons can be explained by the injury-
induced release of bladder neurotrophic factors such as
brain-derived neurotrophic factor, glial-derived neu-
rotrophic factor, and ciliary neurotrophic factor.18,22 In
particular, endogenous levels of nerve growth factor or
NGF signiﬁcantly increase in the bladder wall, lum-
bosacral spinal cord, and dorsal root ganglion after
spinal cord injury.18,22,23 Similarly, exogenous NGF
administration can induce bladder aﬀerent neuron ﬁring
via intravesical administration and segmental spinal
cord micturition reﬂex via spinal cord and bladder wall
administration.20,22,24 Conversely, neutralization of
endogenous NGF by intrathecal application of NGF
antibodies can mitigate detrusor overactivity.25,26
Since it is a widely accepted concept that a target
organ can exert inﬂuence on its innervating neurons, it
is probable that NGF, released by the detrusor smooth
muscle and urothelial cells, is responsible for the
acquired bladder aﬀerent neuron hyperexcitability by
altering their ion channel properties after spinal cord
injury. Indeed, hyperexcitable C-ﬁber-mediated sponta-
neous detrusor contractions and spinal cord segmental
reﬂex voiding can be induced in chronic spinal-injured
cats; this segmental reﬂex has a characteristic shorter
central delay of 15 ms compared to the 60-ms delay in
the normal supraspinal micturition reﬂex mediated by
the spinobulbospinal pathway in spinal-intact cats.27
Similarly, in spinal-injured human and veterinary
patients in which the supraspinal control that mediates
simultaneous detrusor contraction and outlet relaxation
is lost, C-ﬁber-mediated spinal cord segmental micturi-
tion reﬂex can trigger concurrent detrusor and sphincter
contractions, which can in turn lead to ineﬃcient blad-
der emptying, high residual volume, bladder overdisten-
sion, and detrusor hypertrophy from chronic, persistent
intravesical pressure elevation.11,12,14,15
Furthermore, C-ﬁber aﬀerent input undergoes seg-
mental and supraspinal neuromodulation within the
spinal cord and the brain before triggering the activa-
tion of autonomic and somatic eﬀerent pathways.
Spinal cord interneurons modulate both segmental mic-
turition reﬂex and supraspinal communication. In
response to an excitatory aﬀerent input, the interneu-
rons located dorsal to their eﬀerent autonomic
preganglionic neurons can in turn trigger neuronal
excitation.18,28–30 This disynaptic “aﬀerent-interneuron-
eﬀerent” segmental reﬂex is thought to underlie the
micturition reﬂex in neonates, which rely on “perineal-
to-bladder” or “perigenital-to-bladder” reﬂex elicited by
the mother licking the newborn’s perineum or perigeni-
tal area.15,28 In neonatal rats, the excitatory eﬀect of
interneurons on the autonomic preganglionic neurons
can decrease by 50% during the third postnatal week,
which coincides with the development of spinobul-
bospinal pathways.18,28,29
Conversely, spinal cord transection by day 14 in
neonatal rats, which is before the establishment of
supraspinal dominance, can free the segmental micturi-
tion reﬂex from supraspinal suppression.18,28,29 Clini-
cally, the C-ﬁber-mediated segmental micturition reﬂex
can be induced by means such as intravesical cold water
infusion in chronic spinal-injured human patients and
in normal infants, but not in spinal-intact adults.18,31–33
Therefore, it appears that humans and rats are naturally
born with segmental spinal micturition reﬂexes but, as
the supraspinal pathways emerge during postnatal
development, the synaptic eﬃcacy of the interneuron-
mediated segmental reﬂex diminishes and remains sup-
pressed unless supraspinal pathways become damaged
and inherent neuroplasticity revives the dormant seg-
mental micturition reﬂex.
In veterinary medicine, along with other segmental
reﬂexes such as involuntary pelvic limb locomotive
movements, “reﬂex voiding” or involuntary urine void-
ing that can be elicited by segmental aﬀerent stimula-
tion of the perineum, perigenital area, tail, and pelvic
limbs, is commonly observed in pet dogs with chronic,
severe T3–L3 spinal cord injury. These injuries can be
recognized in individuals diagnosed with a modiﬁed
Frankel score of 0 and exhibiting paraplegia and
absence of “deep pain” sensation persisting for more
than 3 months.34 Nevertheless, these animals often
require regular manual bladder expression to prevent
urine retention because the development of detrusor-
sphincter dyssynergia renders reﬂex voiding an ineﬃ-
cient means of urine elimination.18
Clinical Consequences
Spinal cord injury can aﬀect both urine storage and
voiding. After injuries to the sacral spinal cord seg-
ments, both parasympathetic and somatic innervation
to the lower urinary tract can be impaired. In compan-
ion animals, the characteristic clinical signs of severe,
lower motor neuron spinal cord injury are detrusor
hyporeﬂexia or areﬂexia and sphincter hypotonia or
atonia, which can lead to increased bladder compliance,
increased bladder capacity, increased residual volume,
and constant urine leakage. Similarly, in human
patients, complete or severe sacral spinal cord injuries
can cause detrusor and sphincter acontractility and
impaired bladder sensation.35
In contrast, severe, acute, suprasacral spinal cord
injury can abruptly disrupt intraspinal pathways, and
thus eliminate the spinobulbospinal micturition reﬂex.
The initial postinjury period termed “spinal shock” can
last up to 3 months in human patients33, but in pet
dogs its eﬀect on pelvic limb function is only apparent
for 24–48 hours.36 A similar duration of eﬀect has been
reported in experimental dogs that displayed ﬂaccid
paraplegia in the ﬁrst 48–72 hours after spinal cord
transection before regaining muscle tone over 14 days,
whereas the return of urinary bladder tone occurred
over 2–3 weeks.37 During spinal shock, the bladder is
often atonic and areﬂexic, meaning that urine is
retained unless drained by urinary catheterization, inter-
mittent or indwelling, or manual expression.33,36 After
spinal shock, inherent neuroplasticity mediates changes
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such as the emergence of C-ﬁber-mediated segmental
reﬂex in the micturition pathway occurring within
weeks to months after injury; the clinical manifestation
of these changes depend primarily on the location and
severity of the spinal cord injury.33,35,38
Although the sympathetic and supraspinal regulations
of bladder function such as detrusor relaxation during
ﬁlling and coordinated voiding are impaired in upper
motor neuron injury, the sacral parasympathetic and
sacral somatic innervations remain intact, which can
cause involuntary detrusor contraction during ﬁlling
and uncoordinated sphincter contraction during void-
ing. Thus, during ﬁlling, detrusor overactivity produces
periodic elevated intravesical pressure and urine leak-
age; whereas during voiding, detrusor-sphincter dyssyn-
ergia causes ineﬀective bladder emptying, high residual
volume, and high intravesical pressure (Fig 3).33
A large proportion, 21/38 (55%), of chronically para-
lyzed pet dogs have detrusor overactivity, as detected
by cystometry.39 By comparison, detrusor overactivity
and detrusor-sphincter dyssynergia occurs in 95% and
68% of suprasacral spinal-injured human patients,
respectively.35 These functional changes during urine
storage and voiding can lead to complications, such as
vesicoureteral reﬂux and secondary pressure-induced
upper urinary tract injury, as well as increased risks for
urinary tract infection.4,40–44
Normally, the mechanisms of continuous slow urine
inﬂow from the upper urinary tract during bladder ﬁll-
ing and intermittent rapid outﬂow during voiding pre-
vent bacterial ascension, adhesion, and colonization
within the lower urinary tract.45 Urinary tract infections
are more prevalent among spinal-injured individuals
that lack the ability to clear bacteriuria eﬃciently
because of infrequent bladder voiding, high residual
volume, and the increased exposure to uropathogens
that largely results from frequent urinary catheteriza-
tion.33,40,46,47 Urinary tract infections can be classiﬁed
as uncomplicated or complicated; the latter suggests an
underlying cause for increased susceptibility, such as
immunosuppression, immunodeﬁciency, structural, or
neurogenic outﬂow obstruction.48,49
For both complicated and uncomplicated urinary
tract infections in humans and dogs, the most prevalent
uropathogens are the gut Escherichia coli species that
contaminate the periurethral area and ascend to colo-
nize the lower urinary tract. The placement of urinary
catheters can introduce periurethral and environmental
pathogens into the lower urinary tract; whereas the uri-
nary catheters themselves, especially when in-dwelling,
favor bacterial attachment and multiplication, particu-
larly when the patient requires prolonged in-hospital
urinary management.1,2,4,40,46,47 Following adhesion to
urothelium, bacteria digest host cells using toxins and
Fig 3. Clinical consequences of abnormal urine storage and voiding after severe upper motor neuron or suprasacral spinal cord injury.
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proteases, multiply in host cell cytosol, and ascend to
the upper urinary tract, where, if left untreated, fatal
consequences such as pyelonephritis, bacteremia, and
septicemia, can ensue.1,40
Treatment of urinary tract infection usually involves
antibiotics chosen following urinalysis, urine culture,
and susceptibility; frequent exposure to antibiotics can
alter gut commensal microbiota and select for mul-
tidrug-resistant microorganisms.50 Uropathogens can
develop multidrug resistance shortly after antibiotic
exposure by acquiring resistance-encoding plasmids
such as the b-lactamase plasmids, which are capable of
rapidly propagating antibiotic resistance.51–53 Recur-
rences of urinary tract infection can ensue either by
reascension of gut bacteria or recrudescence of a persis-
tent urinary tract nidus such as a quiescent intercellular
bacterial reservoir from a previous infection.45 Thus,
alternative therapeutic options, which will be discussed
below, should be explored for the management of recur-
rent urinary tract infections in spinal-injured veterinary
patients.
In addition to infection-induced morbidity and mor-
tality, neurogenic outﬂow obstruction, and intravesical
pressure elevation after spinal cord injury can lead to
vesicoureteral reﬂux and subsequent upper urinary tract
anatomic and functional deterioration. Vesicoureteral
reﬂux is particularly common in human patients after
complete upper motor neuron spinal cord injuries.41–44
Injuries at T10–L2, where the sympathetic intermedio-
lateral nuclei that mediate sphincter relaxation during
voiding are located, are associated with the highest inci-
dence of vesicoureteral reﬂux.54
In human patients, vesicoureteral reﬂux has been
implicated in renal scarring identiﬁed on ultrasound
examination, proteinuria, reduced glomerular ﬁltration
rate, elevated serum creatinine, reduced creatinine clear-
ance rate, and hypertension.55,56 Furthermore, chronic
vesicoureteral reﬂux can impair nephrogenesis in devel-
oping kidneys.44,57,58 In pediatric human patients, vesi-
coureteral reﬂux is associated with reﬂux nephropathy,
chronic kidney disease, and end-stage renal disease;
whereas in neonatal rodents, vesicoureteral reﬂux can
lead to tubular cell ischemia and atrophy, glomeru-
losclerosis, epithelial apoptosis, and peritubular
ﬁbrosis.42,59,60
Lastly, although poorly investigated in veterinary
patients, autonomic dysreﬂexia is a well-documented,
potentially life-threatening condition that typically aﬀects
human patients who have chronic, severe spinal cord
injuries at the level of T6 or higher.33,57,58 Damage to
the descending vasomotor pathways and sympathetic
preganglionic neurons in the thoracolumbar intermedio-
lateral nucleus and their aﬀerent input can impair auto-
nomic regulation of the cardiovascular function.61 As a
result, autonomic stimuli, such as distension or irritation
of the urinary bladder or colon, can trigger unregulated,
excessive sympathetic preganglionic neuron ﬁring, which
typically manifests as hypertension and baroreﬂex-
mediated compensatory bradycardia; the former can
increase the risk of intracranial hemorrhage.33,57,58,62
Autonomic dysreﬂexia can be a permanent risk in the
chronic phase of spinal cord injury in a subset of
patients and often occurs as the result of autonomic or
somatic stimulation below the level of the spinal cord
lesion.57,58,61,62 Thus, regular bladder and colon evacua-
tion are recommended for the prevention of this
potentially life-threatening condition; pharmacological
agents such as lidocaine and bupivacaine can also be
helpful.57,58,61,62
In conclusion, despite the similar clinical features that
spinal-injured veterinary patients share with their human
counterparts, many serious complications that have been
extensively investigated and carefully addressed in
human medicine are yet to be identiﬁed in animals.
Cystometric Evaluation of Neurogenic Lower
Urinary Tract Dysfunction
Cystometry is a urodynamic procedure that measures
the ﬁlling and voiding functions of the lower urinary
tract. It is indicated for diagnostic and monitoring pur-
poses in human patients who show clinical signs of uri-
nary incontinence, including those caused by neurogenic
lower urinary tract dysfunction.63,64 Data on intravesi-
cal pressure, bladder storage capacity, detrusor overac-
tivity, and bladder compliance can be obtained using
this diagnostic tool. Furthermore, when combined with
sphincter electromyogram, cystometry can be used to
diagnose detrusor-sphincter dyssynergia, which is char-
acterized by uncoordinated simultaneous contractions
of the detrusor and the urethral sphincter.
In veterinary medicine, cystometry is currently uncom-
monly used for clinical purposes, but provides useful
data for dogs enrolled in clinical studies or prehuman
trials.39 It can be performed on conscious or lightly
sedated animals in lateral recumbent or standing posi-
tions using commercial urodynamic systems. A dual-
lumen urinary catheter is placed aseptically, one lumen is
used to measure the intravesical pressure and the other
allows intravesical infusion of a sterile solution to ﬁll the
bladder. Infusion is normally stopped when leaking is
apparent at the external ureteral oriﬁce or, for patient
safety, when a certain volume or intravesical pressure
threshold is reached.
In severe, chronic T3–L3 spinal-injured pet dogs,
detrusor overactivity can lead to altered cystometric
outcome measures, especially reduced bladder compli-
ance and capacity (Fig 4). Bladder compliance is a mea-
sure of the bladder wall response to stretching during
ﬁlling and it is deﬁned as the amount of change in
intravesical pressure associated with a speciﬁc change in
intravesical volume or DV/DPves. Although 12.5–30 mL/
cmH2O has been used as the lower end of normal in
humans, bladder compliance can vary greatly among
both spinal-intact and spinal-injured individuals, render-
ing its interpretation problematic.39,63–66
Bladder capacity can be measured by comparing the
total volume infused with the maximum physiologic
storage capacity. Although the generally accepted safe,
intravesical pressure threshold is in the vicinity of 40–
50 cmH2O for humans,
63–67 the physiologic bladder
capacity is yet to be determined, although 300–600 mL
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per patient has been used in most human studies.63–67
In our cystometry studies, we have used a value of
20 mL/kg for estimating normal bladder capacity in
spinal-injured pet dogs derived from a reported value of
18 mL/kg in dogs.13
A rectal transducer placed before infusion will simul-
taneously measure the abdominal pressure Pabd, which
can be subtracted from the intravesical pressure Pves to
obtain the net detrusor pressure Pdet, or
Pves = Pdet + Pabd. However, the rectal transducer can
produce misleading results if placed inappropriately
such as contacting rectal wall or in feces.67–70 Addition-
ally, the rectal transducer can trigger, usually transient,
detrusor contraction and subsequent voiding, defeca-
tion, and excessive pelvic limb and tail movement in
T3–L3 spinal-injured pet dogs, likely because of the
unsuppressed segmental aﬀerent stimulation.
Finally, there are several diﬃculties with cystometry,
especially when used in animals. Some examples
include: (1) the typical cystometric infusion rate of 60–
120 mL/kg/h used in dogs is considerably higher than
the physiologic urine output rate of 1–2 mL/kg/h; (2)
stress-induced confounders such as excessive abdominal
movement during the procedure, typically resulting
from the unfamiliar environment and handlers, can ren-
der the results diﬃcult to interpret; (3) the body posi-
tion might not be reproducible at repeated
measurement sessions if the dog is uncooperative; and,
(4) triggers of detrusor contraction other than bladder
wall stretching such as rectal transducer placement,
rapid infusion rate, and excessively cool infusion ﬂuid
temperature, all can aﬀect the interpretation of the
results.
Furthermore, in addition to catheterization-induced
tissue trauma and potential ascending urinary tract
infection, infusion-induced bladder distension has been
documented to cause discomfort and autonomic dysre-
ﬂexia in some human spinal-injured patients.33,57,58,62,63
Thus, cystometry should be performed with caution
under close observation for signs of discomfort or stress
in veterinary patients. Prophylactic antibiotics can be
given around the time of the procedure at the clinician’s
discretion.64 Although autonomic dysreﬂexia is not yet
an established complication in veterinary medicine, it is
also advisable for dogs with cranial thoracic spinal cord
injuries to have blood pressure, heart rate, and respira-
tory rate monitored during the procedure.
In summary, cystometry enables clinicians to objec-
tively diagnose and monitor neurogenic lower urinary
tract dysfunction. In spinal-injured individuals, cystom-
etry is especially useful in recognizing detrusor overac-
tivity and detrusor-sphincter dyssynergia, which can
lead to many serious complications. In veterinary medi-
cine, cystometry may become a useful part of our rou-
tine assessment of veterinary patients following acute
spinal cord injury because cystometric abnormalities,
such as increased storage intravesical pressure and
reduced bladder compliance, are common.39,65
Management Considerations
The type and severity of neurogenic lower urinary
tract dysfunction depend on the location and severity of
the injury. Anatomically, neurogenic lower urinary tract
dysfunction can be classiﬁed as: (1) suprapontine,
implying primarily forebrain; (2) pontine; (3) suprasa-
cral spinal cord; (4) sacral spinal cord; and (5) subsacral
including the peripheral nerves innervating the lower
urinary tract, or lower motor neuron. Collectively, the
ﬁrst three components constitute the “upper motor
neuron.”
Current long-term urological management of suprasa-
cral spinal-injured animals is limited to treating urinary
tract infections and assisting voiding, mainly by manual
bladder expression. However, in paraplegic dogs, man-
ual bladder expression is ineﬃcient because only ~50%
of the bladder volume can be emptied, resulting in sub-
stantially higher residue volumes of 0.50–33.02 mL/kg
in paraplegic dogs66 compared to the values of 0.2–
0.4 mL/kg in normal dogs.67 Thus, a consensus address-
ing various aspects of neurogenic lower urinary tract
dysfunction, from initial diagnosis to long-term
Fig 4. Cystometry recording in pet dogs with spinal cord injury. Top panel: abnormal detrusor contractions (arrows) recorded in an 8-
year-old French bulldog that had intervertebral disk herniation at T13–L1 1 year previously and did not recover continence or walking.
Lower panel: an unremarkable cystometry recording in a 7-year-old Beagle that had T11–T12 intervertebral disk herniation 2 years
previously.
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management, should standardize and improve our cur-
rent practices. The following discussion pertains to
acute, traumatic T3–L3 spinal cord injuries unless
otherwise stated.
Clients need to be informed as early as possible as to
the degree of likely neurogenic lower urinary tract dys-
function and associated prognosis because home-based
management can be challenging and time-consuming,
requiring a median of 3 hours per week and up to
16 hours per week for a chronically paraplegic dog.68
Immediately after severe acute spinal cord injury, ani-
mals can experience a period of spinal shock that is
characterized by the transient absence or depression of
spinal reﬂexes caudal to the lesion.36 During this period,
the urinary bladder passively distends but the detrusor
cannot contract;33 thus, assisted bladder voiding is often
required to prevent bladder overdistension and urinary
tract infection. The frequency of bladder palpation and
assisted voiding by manual expression or urinary
catheterization can be adjusted according to the individ-
ual patient’s ﬂuid intake; this is especially important
during ﬂuid supplementation at supraphysiologic rates
such as during general anesthesia for diagnostic imaging
and surgery.
It is well-established that patients may take as long
as 3 months, or even more, to regain ambulation after
severe acute spinal cord injury and, if it occurs, lower
urinary tract function often recovers over a similar per-
iod of time. Our recent study suggests that neuroplastic-
ity-mediated detrusor overactivity can emerge during
this period in some spinal-injured pet dogs.39 Therefore,
if patients fail to regain normal micturition function
after the initial spinal cord injury, owners should be
informed on the likelihood and educated on the impor-
tance and practices of long-term, possibly lifelong, man-
agement of lower urinary tract dysfunction. These
patients are at high risk for recurrent urinary tract
infections and repeated use of antibiotics can lead to
high rates of multidrug-resistant infections. To avoid
this complication in dogs that appear susceptible, we
would recommend using antibiotics only after culture
and susceptibility testing and greater use of nonspeciﬁc
urinary antiseptics, such as methanamine, nitofurantoin,
and acidiﬁers. Periodic testing of kidney function and
urine culture and susceptibility testing are advisable
even in nonsymptomatic animals.
Cystometry testing forms an important part of man-
agement in human paraplegic patients and may aid in
management of similarly aﬀected dogs. In humans it is
recognized to improve the decision-making process for
management of incontinence and long-term outcome.69
Cystometry might be useful to identify, at an early stage,
whether manual bladder expression is successful at main-
taining bladder storage capacity and normal compliance.
Our recent studies have suggested that ~70% of chronic
paraplegic dogs may develop low bladder compliance.39
If these cases could be identiﬁed at an early stage, possi-
bly within 1–3 months of injury, this problem could be
averted. Similarly, identiﬁcation of dogs that have very
high bladder pressures could allow the potential problem
of renal injury through vesicoureteric reﬂux and possibly
secondary pyelonephritis to be averted through use of
appropriate antimuscarinic drugs, as discussed below.
Current and Potential Therapies
The treatment goals for neurogenic lower urinary
tract dysfunction are to stop urine leaking because of
detrusor overactivity during bladder ﬁlling, to preserve
upper urinary tract integrity by reducing intravesical
pressure and vesicoureteral reﬂux, and to treat and pre-
vent urinary tract infections.
Medical Management of Neurogenic Lower Urinary
Tract Dysfunction
Antimuscarinic agents, or muscarinic receptor antag-
onists, such as darifenacin, fesoterodine, and oxybu-
tynin oral medications, work by competitively binding
with the bladder wall muscarinic receptors that are acti-
vated by acetylcholine-receptor binding; the parasympa-
thetic-mediated detrusor contractions during bladder
ﬁlling can be mitigated by inhibiting cholinergic neuro-
transmission.70–72 The development of newer antimus-
carinics with extended-release oral formulations and
higher receptor selectivity has enhanced the clinical util-
ity of this class of drugs for treating lower urinary tract
dysfunction in spinal-injured human patients with
suprasacral injuries.73
Botulinum neurotoxins such as onabotulinumtoxin-A,
also known as Botoxin, intradetrusor injection also
have antimuscarinic eﬀect. Botulinum neurotoxins inter-
fere with acetylcholine exocytosis at the parasympa-
thetic presynaptic membrane.70,71,74 Additionally,
clinical studies suggest that bladder wall botulinum neu-
rotoxin injection can abolish detrusor overactivity in
spinal-injured individuals by reducing the urine and
bladder wall nerve growth factor levels and thus activa-
tion of the hypermechanosensitive C-ﬁber aﬀerents in
the bladder wall.75
Alternatively, detrusor overactivity can be inhibited
in spinal-injured human patients by directly suppressing
the C-ﬁber-mediated bladder aﬀerent hyperexcitability
by administrating vanilloids such as capsaicin and resin-
inferatoxin. Vanilloid receptors, or VR1, can become
upregulated after spinal cord injury.76 After intravesical
or intradetrusor delivery, vanilloid binding with the C-
ﬁber vanilloid receptors, or transient vanilloid receptor
1, can trigger transient depolarization in the aﬀerent
neurons followed by a prolonged period of inactivation,
which leads to C-ﬁber aﬀerent desensitization and
reduced excitability in response to bladder wall aﬀerent
input.77–79
Additionally, opioid receptor agonists and antago-
nists have been extensively investigated for treating neu-
rogenic lower urinary tract dysfunction.80–84 Opioid
receptors are widely distributed within central nervous
system micturition pathways, including locations such
as the spinal cord parasympathetic nucleus, pontine
micturition center and periaqueductal gray. Currently,
opioids are not considered standard treatment for neu-
rogenic detrusor overactivity and detrusor-sphincter
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dyssynergia in spinal-injured human patients, due lar-
gely to their signiﬁcant side-eﬀects, which include con-
stipation, nausea, vomiting, respiratory depression, dry
mouth, drug tolerance, dependence, and addiction when
administered as analgesics for treating post injury or
post surgery pain and chronic central neuropathic
pain,85–88 as well as their speciﬁc impact on the neuro-
logic outcome following acute, traumatic spinal cord
injury.
For instance, in spinal-injured experimental rats, high-
dose systemic morphine administration at 20 mg/kg
within 24 hours post injury can lead to central neuro-
pathic pain 3 weeks post injury; when delivered
intrathecally, morphine administration can result in
worse locomotor recovery and increased mortality.89 It
is thought that opioid administration can potentiate
traumatic spinal cord injury-induced neuronal excito-
toxicity and gliopathy, resulting in additional secondary
spinal cord injury and thus worsened clinical out-
come.90–93 Moreover, opioid administration via oral,
intravenous, and epidural routes have been associated
with higher risks of urine retention by increasing blad-
der storage capacity and compliance via mechanisms
including inhibition of bladder sensory innervation for
detecting the degree of bladder distension, sympathetic
overstimulation causing increased sphincter resistance
and direct opioid binding with spinal cord opioid recep-
tors producing detrusor relaxation.94–98
These opioid-induced eﬀects on the lower urinary
tract can lead to secondary complications including
bladder overdistension and reduced contractility, uri-
nary tract infections, autonomic responses, such as
hypertension, bradycardia, and cardiac dysrhythmias,
increased hospital stay and costs, as well as increased
morbidity in human patients.99–102 Nonetheless, experi-
mental and early clinical evidence suggests that opioids,
such as tramadol which is a weak mu-receptor agonist,
U-50488 which is a kappa-receptor agonist and mor-
phine which is a pure mu- and kappa-receptor agonist,
can mitigate detrusor overactivity and detrusor-sphinc-
ter dyssynergia and improve voiding eﬃciency.81–84
Other potential therapeutic agents that target various
sites within the peripheral and central micturition neu-
romodulatory pathways are mostly still at the experi-
mental or early clinical stages of drug development.
These potential therapeutics include agents that modu-
late bladder aﬀerent ion channels such as Na+, K+,
and Ca2+ ion channels, antibody treatment for reducing
the levels of spinal cord injury-induced nerve growth
factor, and a- and b-adrenergic agents that regulate
sympathetic-mediated neurotransmission.70,103,104
Pharmacologic Intervention for Urinary Incontinence
in the Acute Phase of Spinal Cord Injury in Dogs
Parasympathomimetic drugs such as bethanechol and
carbachol have been used in dogs that have bladder
atony, with the aim of contracting the detrusor, and
thereby inducing urine voiding. However, there are cur-
rently no data available to conﬁrm clinical eﬃcacy of
these drugs in treating bladder dysfunction as the result
of spinal cord injury in companion animals. For
instance, in one study on normal dogs, administration
of bethanechol for 15 days was not associated with
changes in either urethral or bladder pressure.105 Other
potential pharmacological detrusor contraction stimula-
tors including cholinesterase inhibitors like neostigmine
and pyridostigmine, beta agonists like propanalol, pros-
taglandin, and cisapride have not been systematically
investigated in veterinary medicine.106
Because the smooth and striated urethral sphincters
are under sympathetic and somatic nervous system con-
trol, respectively, a-sympatholytic drugs, such as pra-
zosin, alfuzosin, and phenoxybenzamine, and striated
muscle relaxants like diazepam, dantrolene, and baclo-
fen may seem appropriate for inducing urethral sphinc-
ter relaxation and assisting urine voiding. However,
experimental evidence for their eﬃcacy is very limited.
Experiments in anesthetized cats107–109 that are already
experiencing an anesthetic agent-induced muscle relax-
ation eﬀect suggest that the urethral pressure changes
triggered by dantrolene, dantrolene plus prazosin,
prazosin, acepromazine, and phenoxybenzamine are
highly variable, and are therefore not conclusively sup-
portive of their putative eﬀect of urethral pressure
reduction.
For instance, a 20%, or 2.7 cmH2O, reduction in ure-
thral pressure was noted in some tests, but the clinical
importance of this apparently small eﬀect is unknown;
similar experiments in conscious healthy male cats also
detected considerable variation in recorded pressures
and very few consistent changes in urethral pressures
associated with phenoxybenzamine or diazepam admin-
istration.107–110 On the other hand, there is some weak
experimental evidence in male cats supportive of the
putative urethral relaxation eﬀect of alfuzosin,111 as well
as evidence supporting the use of prazosin in reducing
urethral pressure in nonsedated healthy dogs112 and ter-
azosin in treating dogs with reﬂex dyssynergia.113
Surgical Management of Neurogenic Lower Urinary
Tract Dysfunction
A surgical technique similar to sacral cranial root
stimulation or SARS, an established surgical treatment
option for human patients with detrusor overactivity
and detrusor-sphincter dyssynergia,114 is clinically avail-
able to spinal-injured pet dogs that are unable to initiate
voluntary urine voiding.115 Sacral ventral root stimula-
tion in dogs involves the surgical isolation and placement
of silicon-insulated platinum electrodes around S2 spinal
nerves bilaterally. The electrodes are attached to a sub-
cutaneous receiver coil, which can be activated transcuta-
neously with an external stimulator that triggers S2
ﬁring and subsequent detrusor contraction and bladder
emptying “on demand.” This surgical technique provides
a voiding eﬃciency of >90% in 8 of the 9 implanted
dogs, with dogs still using the system 5 years after
implantation.115
Sacral neuromodulation is another surgical technique,
using a diﬀerent type of surgical implant, that can be
used for treatment of neurogenic lower urinary tract
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dysfunction in spinal-injured human patients.116 Cur-
rently it is considered a second-line treatment as an
alternative to antimuscarinic agents for treating an
overactive bladder.38 Although the exact mechanisms
are unknown, implant-mediated sacral nerve stimulation
is thought to promote continence during bladder ﬁlling
and voiding eﬃciency by centrally modulating the
switch between urine storage and voiding.116–118 Fur-
thermore, detrusor overactivity and detrusor-sphincter
dyssynergia can be prevented by implants that deliver
bilateral stimulation via the electrodes at the S3-foramen
during the acute detrusor areﬂexia phase that occurs
during “spinal shock” in spinal-injured human patients.
Sacral neuromodulation is thought to prevent the devel-
opment of abnormal spinal cord segmental micturition
reﬂex post injury by suppressing the activation of the
hypermechanosensitive C-ﬁber aﬀerents.116–118
Several other surgical options including bladder aug-
mentation, urinary diversion, and sphincterotomy have
been utilized to address neurogenic lower urinary tract
dysfunction secondary to spinal cord injury but most
are no longer considered a standard treatment for sev-
eral reasons: (1) some, such as bladder augmentation,
have been replaced by more eﬀective medical and surgi-
cal treatment options mentioned above; (2) some, such
as urinary diversion, only apply to a small subset of
patients and would thus usually only be recommended
if all other more established treatment options have
failed; and (3) some are not favored because of their
associated complications; for instance, sphincterotomy
can improve voiding eﬃciency by reducing bladder out-
let resistance but it can also lead to urinary inconti-
nence during bladder ﬁlling.38,116–118
Management of Lower Urinary Tract Infection
Long-term management of complicated urinary tract
infection in spinal-injured veterinary patients can be
particularly challenging and costly. Multidrug-resistant
uropathogen isolates are more prevalent in complicated
urinary tract infections in dogs and they account for
over one-third of the common uropathogens such as
Escherichia coli and Staphylococcus species.119 There-
fore, urine culture and susceptibility should always be
performed before starting antibiotic treatment because
the long-term harm of empirical antibiotic treatment
while pending culture and susceptibility results can out-
weigh any perceived short-term gain in systemically
stable animals that might not require immediate antibi-
otic treatment.
Another consideration regarding the use of antibiotics
for treating urinary tract infections is their urine pH-
dependent eﬃcacy. For instance, although the ﬂuoro-
quinolones and aminoglycosides are most eﬃcacious in
alkaline pH conditions, tetracyclines and many b-lactams
generally work better in acidic environments. On the
other hand, many other drugs including clindamycin,
amoxicillin, and clavulanic acid, are largely pH indepen-
dent.120 Thus, dietary or pharmacological urine pH
manipulation, which is easy in clinical patients, may
potentiate the eﬃcacy of the antibiotics of choice and
thus should be considered when planning treatment for
complicated urinary tract infections.
Nonetheless, preventative strategies should be the
focus of long-term urinary tract infection management.
These include: (1) good hygiene practices to reduce gut
uropathogen exposure and ascension; (2) frequent
assisted bladder voiding to periodically eliminate bac-
teriuria and prevent bacteria adhesion; and, (3) long-
term daily nonantibiotic prophylactics such as urine
acidiﬁers like ammonium chloride and urinary tract
antiseptics like nitrofurantoin, methenamine hippurate,
and methenamine mandelate to render bacterial colo-
nization and multiplication unfavorable. Although these
nonantibiotic prophylactics have demonstrated eﬃcacy
in preventing the recurrence of urinary tract infections
in some studies including one in which a 5.4-fold reduc-
tion during nitrofurantoin prophylaxis was reported in
219 women121, adverse eﬀects including nausea and
acute pulmonary reactions and injuries have also been
documented.121,122
In future, the development of novel therapies for uri-
nary tract infection might also help with the manage-
ment of spinal-injured veterinary patients. Recent
human clinical trials suggest that combination therapies
involving diﬀerent classes of newer antibiotics, such as
the combination of a third-generation cephalosporin
ceftazidime and a novel non-b-lactam b-lactamase inhi-
bitor, avibactam,40,123 might be useful for treating
multidrug-resistant uropathogens in spinal-injured vet-
erinary patients. Many novel synthetic compounds tar-
geting alternative aspects of the pathogenic mechanisms
of urinary tract infections, such as the bacterial pili that
mediate uroepithelial adhesion, are still at early stages
of drug development.124–128 In addition, bacterial pili,
along with other pathogenic compounds including bacte-
rial adhesins, toxins, proteases, and siderophores, have
been the targets of antivirulence host-immunotherapy
and vaccine development.129–131
Conclusion
The neuroplasticity-mediated pathologic changes after
severe, acute spinal cord injury often impair lower uri-
nary tract function and can signiﬁcantly impact on the
quality of life and life expectancy of spinal-injured vet-
erinary patients. Clients should be informed regarding
the likely severity of spinal cord injury-induced neuro-
logic impairment and prognosis as early as possible and
educated on the long-term management considerations
and potential therapeutic options if their pets fail to
recover by ~3 months post injury. If their eﬃcacy can
be demonstrated in well-designed, reproducible veteri-
nary clinical trials, therapies that are designed to
address common neurogenic lower urinary tract dys-
function as the result of spinal cord injury, including
recurrent urinary tract infection, inability to maintain
urinary continence during bladder ﬁlling, and inade-
quate bladder emptying, may beneﬁt veterinary patients
in the future.
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